$0.10 EPS Expected for BioSyent Inc. (RX)

March 1, 2018 - By reb123z

 $0.10 EPS Expected for BioSyent Inc. (RX)

Analysts expect BioSyent Inc. (CVE:RX) to report $0.10 EPS on March, 21.They anticipate $0.02 EPS change or 25.00 % from last quarter’s $0.08 EPS. V_RX’s profit would be $1.45 million giving it 22.63 P/E if the $0.10 EPS is correct. After having $0.09 EPS previously, BioSyent Inc.’s analysts see 11.11 % EPS growth. It closed at $9.05 lastly. It is down 0.00% since March 1, 2017 and is . It has underperformed by 16.70% the S&P500.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company has market cap of $131.18 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. It has a 27.34 P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

More notable recent BioSyent Inc. (CVE:RX) news were published by: Marketwired.com which released: “BioSyent Pharma Launches New Urgent Care Product” on November 14, 2016, also Marketwired.com with their article: “BioSyent Releases Q1 2017 Results” published on May 25, 2017, Globenewswire.com published: “BioSyent Announces Changes to Its Board of Directors” on January 08, 2018. More interesting news about BioSyent Inc. (CVE:RX) were released by: Marketwired.com and their article: “BioSyent Releases Results for Fourth Quarter and Full Year 2016” published on March 15, 2017 as well as Marketwired.com‘s news article titled: “BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular …” with publication date: May 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: